Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes.

Griffin SJ, Leaver JK, Irving GJ. · 2017

Read Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes. by Griffin SJ, Leaver JK, Irving GJ. (2017) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc5552849.txt.

Introduction

Griffin, Leaver, and Irving present a meta-analysis in Diabetologia. Their question is whether metformin cuts heart disease risk in type 2 diabetes. The drug is the most prescribed oral glucose-lowering medicine in the world. Past reviews had raised doubts on this point.

The team pooled 13 trials with about 2,079 people on metformin. A like number served in comparison groups. Most outcomes leaned toward metformin, but none reached statistical significance. One large British study supplied most of the data. Event counts were small. The authors say real uncertainty remains. They suggest health records and new trial designs to close the gap. Readers get a frank view of thin evidence behind a first-line drug.

Catalog record

CREATORGriffin SJ, Leaver JK, Irving GJ.
YEAR2017
COLLECTIONPAPERS
FORMATTXT
FILE SIZE37 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC5552849

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Impact of metformin on cardiovascular disease: a meta-analysis of randomised trials among people with type 2 diabetes By Simon J Griffin, James K Leaver, Greg J Irving Published in: Diabetologia DOI: 10.1007/s00125-017-4337-9 ABSTRACT Abstract Aims/hypothesis Metformin is the most-prescribed oral medication to lower blood glucose worldwide. Yet previous systematic reviews have raised doubts about its effectiveness in reducing risk of cardiovascular disease, the most costly complication of type 2 diabetes. We aimed to systematically identify and pool randomised trials reporting cardiovascular outcomes in which the effect of metformin was ‘isolated’ through comparison to diet, lifestyle or placebo. Methods We performed an electronic literature search of MEDLINE, EMBASE and the Cochrane Library. We also manually screened the reference lists of previous meta-analyses of trials of metformin identified through a MEDLINE search. We included randomised controlled trials of adults with type 2 diabetes comparing any dose and preparation of oral metformin with no intervention, placebo or a lifestyle intervention and reporting mortality or a cardiovascular outcome. Results We included ten articles reporting 13 trials (including a total of 2079 individuals with type 2 diabetes allocated to metformin and a similar number to comparison groups) of which only four compared metformin with placebo and collected data on cardiovascular outcomes. Participants were mainly white, aged ≤65 years, overweight/obese and with poor glycaemic control. Summary estimates were based on a small number of events: 416 myocardial infarctions/ischaemic heart disease events in seven studies and 111 strokes in four studies. The UK Prospective Diabetes Study (UKPDS) contributed the majority of data to the summary estimates, with weights ranging from 52.3% for myocardial infarction to 70.5% for stroke. All outcomes, with the exception of stroke, favoured metformin, with limited heterogeneity between studies, but none achieved statistical significance. Effect sizes (Mantel–Haenszel RR) were: all-cause mortality 0.96 (95% CI 0.84, 1.09); cardiovascular death 0.97 (95% CI 0.80, 1.16); myocardial infarction 0.89 (95% CI 0.75, 1.06); stroke 1.04 (95% CI 0.73, 1.48); and peripheral vascular disease 0.81 (95% CI 0.50, 1.31). Conclusions/interpretation There remains uncertainty about whether metformin reduces risk of cardiovascular disease among patients with type 2 diabetes, for whom it is the recommended first-line drug. Although this is mainly due to absence of evidence, it is unlikely that a definitive placebo-controlled cardiovascular endpoint trial among people with diabetes will be forthcoming. Alternative approaches to reduce the uncertainty include the use of electronic health records in long-term pragmatic evaluations, inclusion of metformin in factorial trials, publication of cardiovascular outcome data from adverse event reporting in trials of metformin and a cardiovascular endpoint trial of metformin among people without diabetes. Electronic supplementary material The online version of this article (doi:10.1007/s00125-017-4337-9) contains a slideset of the figures for download, which is available to authorised users. Keywords: Cardiovascular disease, Meta-analysis, Metformin, Review, Systematic review INTRODUCTION The aims of prescribing medication to lower glucose among people with type 2 diabetes are to reduce the symptoms of hyperglycaemia and the risk of microvascular and macrovascular complications. Since ancient times, a range of therapies have been effective at alleviating the polydipsia and polyuria associated with raised blood glucose levels. Twenty years ago, trial evidence finally emerged showing that lowering blood glucose reduced risks of microvascular complications among people with type 2 diabetes [1]. However, subsequent randomised trials evaluating the effects of intensive treatment for the regulation of blood glucose have highlighted concerns about adverse effects, in particular hypoglycaemia and mortality, and demonstrated inconsistent findings for risk of micro- and macrovascular complications [2, 3]. The evidence of benefit appears stronger for micro- than macrovascular disease [4], albeit the latter represents the greatest burden to healthcare and society. The situation is further complicated by the heterogeneity in findings of observational studies [5] and randomised trials of different drugs (and combinations of drugs [6]) used to lower blood glucose, even those with apparently similar pharmacological targets [7–10]. The biguanide metformin has had an interesting history. After an inauspicious debut, a somewhat circuitous route (including use as a treatment for infectious disease), the withdrawal of phenformin and buformin (the only other biguanides used to lower blood glucose) following trial evidence of harm [11] and publication of the UK Prospective Diabetes Study (UKPDS) results, showing evidence of cardiovascular benefits [12], metformin was introduced in the USA in 1995 and has emerged as the first-choice and most-prescribed oral medication to lower blood glucose worldwide [13]. However, recent systematic reviews have raised doubts about the effectiveness of metformin in reducing risk of complications [14, 15]. In these reviews, data were pooled from predominantly small trials with short follow-up in which metformin was evaluated against a range of comparators that have heterogenous associations with risk of cardiovascular disease. This has constrained interpretation of the benefits and harms of metformin. Since 2008, the US Food and Drug Administration (FDA) have required demonstration of cardiovascular safety prior to the licensing of new glucose-lowering drugs. Several placebo-controlled trials of glucose-lowering drugs, incorporating cardiovascular endpoints, have reported findings or are underway [16]. Consequently, the availability of data to inform treatment guidelines and prescribing decisions for patients is increasing. In this changing context, it therefore seems timely to review the evidence for cardiovascular disease prevention with metformin. As part of a series of papers to acknowledge the sixtieth anniversary of the first use of metformin for the treatment of type 2 diabetes in this issue of Diabetologia, we appraise the evidence concerning the effectiveness of metformin in preventing cardiovascular disease in patients with type 2 diabetes by undertaking a meta-analysis. We aimed to systematically identify and pool randomised trials reporting cardiovascular outcomes in which the effect of metformin was ‘isolated’ through comparison to diet, lifestyle or placebo, rather than alternative glucose-lowering medication. METHODS We undertook a systematic review and meta-analysis following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines [17]. Search strategy We performed an electronic literature search of MEDLINE (1 January 1967 to 6 February 2017; www.ncbi.nlm.nih.gov/m/pubmed), EMBASE (1 January 1947 to 28 February 2017; https://login.webofknowledge.com) and the Cochrane Library (1 January 1967 to 28 February 2017; www.cochranelibrary.com;), with no language limits, using search terms (shown in the Text box) adapted from an earlier Cochrane review [18]. We also performed an electronic literature search of MEDLINE, with no language or date limits, for papers with ‘meta-analysis’ and ‘metformin’ in the title. We manually screened the reference lists of identified meta-analyses. Finally, we manually screened the reference list of a recent systematic review of cardiovascular endpoint trials of glucose-lowering medication [16]. Study selection We included studies if they fulfilled all of the following criteria: randomised controlled trial among adults with type 2 diabetes comparing any dose and preparation of oral metformin with no intervention, or with placebo or a lifestyle intervention, and reporting mortality or a cardiovascular outcome (cardiovascular death, myocardial infarction, stroke or peripheral vascular disease) as a primary or secondary outcome or adverse event. There was no restriction based on duration of follow-up. We included studies in which metformin was combined with another drug as long as the comparator group was given the other drug at the same dose as used in the metformin combined therapy group, thereby controlling for the effects (either positive or negative) of the other drug and ‘isolating’ the

Read the complete text